Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.
Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournaras CJ, Zografos L, Piguet B, Donati G, Laqua H, Barbazetto I, Gragoudas ES, Lane AM, Birngruber R, van den Bergh H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. Sickenberg M, et al. Among authors: pournaras cj. Arch Ophthalmol. 2000 Mar;118(3):327-36. doi: 10.1001/archopht.118.3.327. Arch Ophthalmol. 2000. PMID: 10721954 Clinical Trial.
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Blumenkranz MS, et al. Arch Ophthalmol. 2002 Oct;120(10):1307-14. doi: 10.1001/archopht.120.10.1307. Arch Ophthalmol. 2002. PMID: 12365909 Clinical Trial.
Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.
Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA. Blinder KJ, et al. Ophthalmology. 2003 Apr;110(4):667-73. doi: 10.1016/s0161-6420(02)01998-x. Ophthalmology. 2003. PMID: 12689884 Clinical Trial.
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES. Miller JW, et al. Among authors: pournaras cj. Arch Ophthalmol. 1999 Sep;117(9):1161-73. doi: 10.1001/archopht.117.9.1161. Arch Ophthalmol. 1999. PMID: 10496388 Clinical Trial.
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. Schmidt-Erfurth U, et al. Among authors: pournaras cj. Arch Ophthalmol. 1999 Sep;117(9):1177-87. doi: 10.1001/archopht.117.9.1177. Arch Ophthalmol. 1999. PMID: 10496389 Clinical Trial.
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7.
Bressler NM, Bressler SB, Haynes LA, Hao Y, Kaiser PK, Miller JW, Naor J, Potter MJ, Pournaras CJ, Reaves A, Rosenfeld PJ, Schmidt-Erfurth U, Slakter JS, Strong A, Vannier S. Bressler NM, et al. Among authors: pournaras cj. Arch Ophthalmol. 2005 Sep;123(9):1283-5. doi: 10.1001/archopht.123.9.1283. Arch Ophthalmol. 2005. PMID: 16157822 Clinical Trial. No abstract available.
Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G; Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Blinder KJ, et al. Am J Ophthalmol. 2003 Sep;136(3):407-18. doi: 10.1016/s0002-9394(03)00223-x. Am J Ophthalmol. 2003. PMID: 12967792
Verteporfin in Photodynamic Therapy: report no. 5.
Bandello F, Blinder K, Bressler NM, Brown AL, Miller JW, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Slakter JS, Soubrane G, Strong HA, Stur M; VIP Report No. 5 Writing Committee. Bandello F, et al. Ophthalmology. 2004 Nov;111(11):2144. doi: 10.1016/j.ophtha.2004.08.002. Ophthalmology. 2004. PMID: 15522385 No abstract available.
174 results